Regenxbio (RGNX) Total Non-Current Liabilities (2018 - 2025)

Regenxbio's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $349.7 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities rose 72.5% year-over-year to $349.7 million; the TTM figure through Dec 2025 stood at $349.7 million (up 72.5% YoY), while the FY2025 annual figure was $349.7 million, up 72.5% from the prior year.
• Total Non-Current Liabilities was $349.7 million for Q4 2025 at Regenxbio, down from $363.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $366.7 million in Q2 2025 to a low of $178.3 million in Q4 2021.
• Historically, Total Non-Current Liabilities has averaged $248.2 million across 5 years, with a median of $217.2 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities surged 652.67% in 2021, then tumbled 34.3% in 2022.
• A 5-year view of Total Non-Current Liabilities shows it stood at $178.3 million in 2021, then gained by 0.68% to $179.5 million in 2022, then increased by 21.88% to $218.7 million in 2023, then retreated by 7.33% to $202.7 million in 2024, then surged by 72.5% to $349.7 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $349.7 million (Q4 2025), $363.1 million (Q3 2025), and $366.7 million (Q2 2025), per Business Quant data.